• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与 ADHD 相关的症状/与治疗相关的不良副作用及其对 ADHD 成年患者生活质量和工作生产力的影响。

Symptoms associated with ADHD/treatment-related adverse side effects and their impact on quality of life and work productivity in adults with ADHD.

机构信息

Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.

Analysis Group, Inc., Montréal, QC, Canada.

出版信息

Curr Med Res Opin. 2023 Jan;39(1):149-159. doi: 10.1080/03007995.2022.2122228. Epub 2022 Sep 30.

DOI:10.1080/03007995.2022.2122228
PMID:36082503
Abstract

OBJECTIVE

Describe symptoms associated with ADHD/treatment-related adverse side effects among adults with ADHD in the US and assess their impact on quality of life (QoL) and work productivity.

METHODS

An online survey among adults receiving ADHD medications in the US was conducted to collect information relating to symptoms associated with ADHD/treatment-related adverse side effects. Participants were recruited from the panel of a well-established market research firm, Dynata, from 26 July to 30 July 2021 and were included in the study if they met the eligibility criteria and were willing to participate in the survey. Correlations between symptoms and key outcomes (QoL/employment/work impairment) were estimated using linear regression analyses.

RESULTS

Of 585 participants, 95.2% experienced ≥1 symptom associated with ADHD/treatment-related adverse side effects in the past month (average = 5.8 symptoms). The number of symptoms was significantly correlated with reduced QoL, reduced probability of being employed, and increased work/activity impairment. Among subgroups with insomnia/other sleep disturbances and emotional impulsivity/mood lability, 50.4% and 44.7% reported their symptoms had "a lot" or "extremely" negative impact on their overall well-being, respectively.

CONCLUSIONS

Symptoms associated with ADHD/treatment-related adverse side effects are common and have a substantial negative impact on QoL and reduces patients' probability of employment. Improved management of ADHD/treatment-related adverse side effects and more tolerable treatment options have the potential to improve QoL and work productivity among adults with ADHD.

摘要

目的

描述美国 ADHD 患者的症状与 ADHD 相关治疗不良反应,并评估其对生活质量(QoL)和工作生产力的影响。

方法

通过一项在线调查,收集与 ADHD 相关症状和治疗不良反应的信息。参与者来自一家知名市场研究公司 Dynata 的小组,于 2021 年 7 月 26 日至 7 月 30 日进行了此项调查,符合入选标准且愿意参与调查的参与者被纳入研究。使用线性回归分析评估症状与关键结果(QoL/就业/工作障碍)之间的相关性。

结果

在 585 名参与者中,95.2%在过去一个月内经历过≥1 种与 ADHD 相关治疗不良反应的症状(平均 5.8 种症状)。症状数量与 QoL 降低、就业机会减少和工作/活动障碍增加显著相关。在存在失眠/其他睡眠障碍和情绪冲动/情绪不稳定的亚组中,分别有 50.4%和 44.7%的参与者报告其症状对整体幸福感有“很大”或“极其”负面影响。

结论

与 ADHD 相关治疗不良反应相关的症状很常见,对 QoL 有重大负面影响,并降低了患者的就业几率。改善 ADHD 相关治疗不良反应的管理和提供更耐受的治疗选择,有可能提高 ADHD 成年患者的 QoL 和工作生产力。

相似文献

1
Symptoms associated with ADHD/treatment-related adverse side effects and their impact on quality of life and work productivity in adults with ADHD.与 ADHD 相关的症状/与治疗相关的不良副作用及其对 ADHD 成年患者生活质量和工作生产力的影响。
Curr Med Res Opin. 2023 Jan;39(1):149-159. doi: 10.1080/03007995.2022.2122228. Epub 2022 Sep 30.
2
Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study.注意缺陷多动障碍伴执行功能障碍成人患者使用赖氨酸安非他命二甲磺酸盐治疗的自我报告生活质量:一项随机、双盲、多中心、安慰剂对照、平行分组研究。
BMC Psychiatry. 2013 Oct 9;13:253. doi: 10.1186/1471-244X-13-253.
3
Working Conditions, Work Productivity, Quality of Life, and Depressive Symptoms in Undiagnosed Adults with and without Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms During the COVID-19 Pandemic.新冠疫情期间有和没有注意力缺陷多动障碍(ADHD)症状的未确诊成年人的工作条件、工作效率、生活质量及抑郁症状
Neuropsychiatr Dis Treat. 2022 Jul 29;18:1561-1572. doi: 10.2147/NDT.S358085. eCollection 2022.
4
Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.患有注意力缺陷/多动障碍的儿童和青少年的健康相关生活质量。
Pediatrics. 2004 Nov;114(5):e541-7. doi: 10.1542/peds.2004-0844.
5
Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults.成人注意力缺陷多动障碍(ADHD)的认知行为干预措施
Cochrane Database Syst Rev. 2018 Mar 23;3(3):CD010840. doi: 10.1002/14651858.CD010840.pub2.
6
Combined impact of ADHD and insomnia symptoms on quality of life, productivity, and health care use in the general population.在普通人群中,ADHD 和失眠症状对生活质量、生产力和医疗保健使用的综合影响。
Psychol Med. 2022 Jan;52(1):36-47. doi: 10.1017/S0033291720001592. Epub 2020 Jun 29.
7
Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.即刻释放型哌甲酯治疗成人注意缺陷多动障碍(ADHD)。
Cochrane Database Syst Rev. 2021 Jan 18;1(1):CD013011. doi: 10.1002/14651858.CD013011.pub2.
8
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.一项评估维洛沙嗪缓释胶囊治疗成人注意缺陷多动障碍的疗效和安全性的 III 期、随机、双盲、安慰剂对照试验。
CNS Drugs. 2022 Aug;36(8):897-915. doi: 10.1007/s40263-022-00938-w. Epub 2022 Jul 27.
9
Association between quality of life and treatment response in children with attention Deficit Hyperactivity Disorder and their parents.注意缺陷多动障碍儿童及其父母的生活质量与治疗反应之间的关联
J Ment Health Policy Econ. 2014 Sep;17(3):119-29.
10
Parent-proxy EQ-5D ratings of children with attention-deficit hyperactivity disorder in the US and the UK.美国和英国注意力缺陷多动障碍儿童的家长代理版EQ-5D评分
Pharmacoeconomics. 2005;23(8):777-90. doi: 10.2165/00019053-200523080-00004.

引用本文的文献

1
Relationship Between Sleep and Immunology in Attention Deficit Hyperactivity Disorder.注意缺陷多动障碍中睡眠与免疫学的关系。
Int J Mol Sci. 2025 Aug 18;26(16):7967. doi: 10.3390/ijms26167967.
2
ILF-neurofeedback in clinical practice: examining symptom change and performance metrics across diagnostic groups.临床实践中的ILF神经反馈:跨诊断组检查症状变化和性能指标
Front Hum Neurosci. 2025 Jul 30;19:1601187. doi: 10.3389/fnhum.2025.1601187. eCollection 2025.
3
Quality of Life and Caregiver Burden in Adult ADHD, Major Depressive Disorder, and Personality Disorders: A Cross-Sectional Study.
成人注意力缺陷多动障碍、重度抑郁症和人格障碍患者的生活质量与照顾者负担:一项横断面研究
Psychiatr Q. 2025 Jul 16. doi: 10.1007/s11126-025-10189-9.
4
A Matching-Adjusted Indirect Comparison (MAIC) of Centanafadine versus Methylphenidate Hydrochloride in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD): Short-Term Safety and Efficacy Outcomes: Comparaison indirecte ajustée par appariement (MAIC) entre centanafadine et le chlorhydrate de méthylphénidate chez les adultes atteints d'un trouble déficitaire de l'attention avec ou sans hyperactivité (TDAH) : Résultats en matière d'innocuité et d'efficacité à court terme.成人注意力缺陷多动障碍(ADHD)患者中,森他法定与盐酸哌甲酯的匹配调整间接比较(MAIC):短期安全性和有效性结果:成人注意力缺陷伴或不伴多动障碍(ADHD)患者中森他法定与盐酸哌甲酯的匹配调整间接比较(MAIC):短期安全性和有效性结果
Can J Psychiatry. 2025 Jun 2:7067437251342279. doi: 10.1177/07067437251342279.
5
Treatment Preferences of Physicians Treating Adult Patients with Attention-Deficit/Hyperactivity Disorder in the United States and Canada: A Discrete Choice Experiment.美国和加拿大治疗成年注意力缺陷/多动障碍患者的医生的治疗偏好:一项离散选择实验。
Neurol Ther. 2025 Feb;14(1):193-210. doi: 10.1007/s40120-024-00681-y. Epub 2024 Nov 16.
6
A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy. centanafadine 与 lisdexamfetamine、哌甲酯和阿托西汀治疗成人注意缺陷多动障碍的匹配调整间接比较:长期安全性和疗效。
J Comp Eff Res. 2024 Sep;13(9):e240089. doi: 10.57264/cer-2024-0089. Epub 2024 Aug 12.
7
Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release.评估 centanafadine 治疗成人注意缺陷多动障碍:与 lisdexamfetamine dimesylate、盐酸托莫西汀和维洛沙嗪缓释剂的匹配调整间接比较。
J Manag Care Spec Pharm. 2024 Jun;30(6):528-540. doi: 10.18553/jmcp.2024.30.6.528.
8
ADHD Prevalence Among U.S. Children and Adolescents in 2022: Diagnosis, Severity, Co-Occurring Disorders, and Treatment.2022 年美国儿童和青少年注意缺陷多动障碍患病率:诊断、严重程度、共病及治疗。
J Clin Child Adolesc Psychol. 2024 May-Jun;53(3):343-360. doi: 10.1080/15374416.2024.2335625. Epub 2024 May 22.
9
A Post-Hoc Analysis of Emotional Lability With Delayed-Release/Extended-Release Methylphenidate in Children Aged 6 to 12 Years of Age Participating in Two Phase 3 Clinical Trials.两项 3 期临床试验中 6 至 12 岁儿童使用缓释/控释哌甲酯后情绪不稳定的事后分析。
J Atten Disord. 2024 Jun;28(8):1186-1197. doi: 10.1177/10870547241243155. Epub 2024 Apr 10.